This report describes if a person has certain alleles that can affect how quickly a drug is metabolized (broken down) in the body, and may be associated with higher risk of nonresponse or over response to medications, adverse drug reactions and drug toxicities.
Numerous factors can affect response to a medicine, including gender, age, and diet. In spite of that, genetics is also an important element in drug response.
The CYP2C19 gene is a member of the cytochrome P450 gene family, it provides instructions to make the enzyme. The cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) enzyme plays a role in processing or metabolizing a large number of commonly prescribed drugs and drug classes such as antidepressants, benzodiazepines, proton pump inhibitors (PPIs), and others. CYP2C19 metabolic activity level can be classified as ultrarapid , Normal, Intermediate, or poor.
Allele* / Allele*
CYP2C19*1 allele (wild type) is associated with functional CYP2C19-mediated metabolism. CYP2C19*2 is the most common CYP2C19 loss-of-function allele. One variant allele that encodes reduced enzyme function *3. CYP2C19*17 allele creates an increased CYP2C19 expression and activity.
*Allele frequencies are based on published literature reports. In general, there are no population studies that test for all known variant alleles. This report presents well-studied alleles, where the margin of error is likely low. It is difficult to group populations with certainty, because some populations are often admixed, or at the least, a combination of different ethnicities. Therefore, the margin of error is increased when ddifferent subpopulations are grouped together.
cytochrome P450 (CYP450)
Importance: The CYP2C19 gene codes for an enzyme that plays a role in the
processing or metabolizing of at least 10 percent of prescription drugs
cytochrome P450 (CYP450)
Importance: High inter individual variations (polymorphism) of the CYP2D6 gene
have been reported in the scientific literature leading to variations in the
enzyme expression. The CYP2D6 enzyme is involved in the
metabolism or processing of up to 25 percent of
cytochrome P450 (CYP450)
Importance: CYP2C9 gene polymorphisms affect metabolic activity of the
enzyme. CYP2C9 is responsible for the metabolic clearance
of up to 15 to 20 percent of all drugs
undergoing Phase I metabolism
cytochrome P450 (CYP450)
Importance: involved in the metabolism of steroid hormones, vitamins and
certain prescription drugs CYP3A5 may be the most important genetic
contributor to interindividual and interracial differences in
CYP3A mediated drug metabolism..
This gene encodes a cytokine
Importance:Association with Hepatitis C Virus Treatment Response
Order your personalized report.
If you want better insights that can inform your health provider about how you may break down certain medications commonly prescribed to treat pain, depression, anxiety, and other conditions.
The 1000 Genomes Project www.internationalgenome.org
U.S. Food and Drug Administration (FDA) biomarker list
Clinical Pharmacogenetic Implementation Consortium (CPIC)
Payne TH, Corley S, Cullen TA, et al. Report of the AMIA EHR-2020 Task Force on the status and future direction of EHRs. J Am Med Inform Assoc 2015;22:1102–1110.
Wei WQ, Leibson CL, Ransom JE, et al. Impact of data fragmentation across healthcare centers on the accuracy of a high-throughput clinical phenotyping algorithm for specifying subjects with type 2 diabetes mellitus. J Am Med Inform Assoc 2012;19:219–224.
Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526:343–350
Richards S, Aziz N, Bale S, et al.; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405–424.
Rehm HL, Berg JS, Brooks LD, et al.; ClinGen. ClinGen–the Clinical Genome Resource. N Engl J Med 2015;372:2235–2242.
Landrum, M. J., Chitipiralla, S., Brown, G. R., Chen, C., Gu, B., Hart, J., Hoffman, D., Jang, W., Kaur, K., Liu, C., Lyoshin, V., Maddipatla, Z., Maiti, R., Mitchell, J., O'Leary, N., Riley, G. R., Shi, W., Zhou, G., Schneider, V., Maglott, D., Holmes, J.B., Kattman, B. L. ClinVar: improvements to accessing data. Nucleic Acids Res. 2020;48(D1):D835-D844. doi: 10.1093/nar/gkz972. [PubMed PMID:31777943]
Landrum MJ, Kattman BL. ClinVar at five years: Delivering on the promise. Hum Mutat. 2018 Nov;39(11):1623-1630. doi: 10.1002/humu.23641. [PubMed PMID:30311387]
Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Jang W, Karapetyan K, Katz K, Liu C, Maddipatla Z, Malheiro A, McDaniel K, Ovetsky M, Riley G, Zhou G, Holmes JB, Kattman BL, Maglott DR. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067. doi: 10.1093/nar/gkx1153. [PubMed PMID:29165669]
Landrum MJ, Lee JM, Benson M, Brown G, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Hoover J, Jang W, Katz K, Ovetsky M, Riley G, Sethi A, Tully R, Villamarin-Salomon R, Rubinstein W, Maglott DR. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 2016 Jan 4;44(D1):D862-8. doi: 10.1093/nar/gkv122. [PubMed PMID:26582918]
Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, Maglott DR. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014 Jan 1;42(1):D980-5. doi: 10.1093/nar/gkt1113. [PubMed PMID: 24234437]
NCBI Handbook. Melissa Landrum, PhD, Jennifer Lee, PhD, George Riley, PhD, Wonhee Jang, PhD, Wendy Rubinstein, MD, PhD, Deanna Church, PhD, and Donna Maglott, PhD. ClinVar.
[Bookshelf ID: NBK174587]
Polymorphic cytochromes P450 and drugs used in psychiatry.Coutts RT, Urichuk LJ.Cell Mol Neurobiol. 1999 Jun;19(3):325-54. doi: 10.1023/a:1006945715127.PMID: 10319191 Review.
Clinical pharmacogenetics and potential application in personalized medicine.Curr Drug Metab. 2008 Oct;9(8):738-84. doi: 10.2174/138920008786049302.
Smith C. Genomics: SNPs and human disease. Nature. 2005; 16: 435–993.
Singh M, Singh P, Juneja PK, Singh S, Kaur T. SNP-SNP interactions within APOE gene influence plasma lipids in postmenopausal osteoporosis. Rheumatol Int. 2001; 31: 421–423.
Sapkota Y, Mackey JR, Lai R, Franco-Villalobos C, Lupichuk S. Assessing SNP-SNP interactions among DNA repair, modification and metabolism related pathway genes in breast cancer susceptibility. PLoS One. 2013. 8: e64896 10.1371/journal.pone.0064896
Onay VU, Briollais L, Knight JA, Shi E, Wang Y. SNP-SNP interactions in breast cancer susceptibility. Bmc Cancer. 2006; 6: 114
Gerke J, Lorenz K, Cohen B. Genetic interactions between transcription factors cause natural variation in yeast. Science. 2009; 323: 498–501. 10.1126/science.1166426
Nelson MR, Kardia SL, Ferrell RE, Sing CF. A combinatorial partitioning method to identify multilocus genotypic partitions that predict quantitative trait variation. Genome Res. 2001; 11: 458–470.
NCBI's Database of Genotypes and Phenotypes: dbGaP.
Nucleic Acids Res. 2014 Jan;42(Database issue):D975-9. doi: 10.1093/nar/gkt1211. Epub 2013 Dec 1.
ClinVar at five years: Delivering on the promise.
Hum Mutat. 2018 Nov;39(11):1623-1630. doi: 10.1002/humu.23641.PMID: 30311387
Database resources of the National Center for Biotechnology Information.
Nucleic Acids Res. 2014 Jan;42(Database issue):D7-17. doi: 10.1093/nar/gkt1146. Epub 2013 Nov 19.
PMID: 24259429 Free PMC article.
Entrez Gene: gene-centered information at NCBI.Nucleic Acids Res. 2011 Jan;39(Database issue):D52-7. doi: 10.1093/nar/gkq1237. Epub 2010 Nov 28.
The information in this Report is for informational and educational purposes only. It is not intended for direct diagnostic use or medical decision-making. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
*This product provides only a preliminary analytical result. An independent, clinically validated test must be used in connection with the medical trait in question.Limitations: This product analyzes certain genetic variants associated with how quickly a medication is metabolized in the body. This product does not query all possible alleles associated with drug metabolism. Results may change as research advances and permit us to better understand what these genetic variations mean for health. Numerous factors can affect response to a medicine, including gender, age, and diet. Not a diagnostic product. Contains data from dbSNP, ClinVar, 1000 genomes project, COSMIC, dbGaP, dbVAR, EGA and many other sources.
Warning: The software and technology components may be subject to United States
trade secret protection laws and the The Defend Trade Secrets Act.